Global Psoriasis Treatment Market Size, By Drug Class (TNF, Inhibitors, Interleukins Inhibitors) By Type (Plaque Psoriasis, Psoriatic Arthritis), By Route of Administration (Oral, Parenteral/Systemic, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geographic Scope And Forecast

Psoriasis Treatment Market Size And Forecast

Psoriasis Treatment market size was valued at USD 24.67 Billion in 2024 and is projected to reach USD 48.09 Billion by 2031, growing at a CAGR of 8.70% from 2024 to 2031.

• Psoriasis treatment encompasses various approaches, including topical treatments (applied directly to the skin), phototherapy (exposure to ultraviolet light), oral medications, and biologic drugs (targeting specific parts of the immune system). The choice of treatment depends on the severity of the condition, its location on the body, and individual factors such as age and overall health.
• The primary goal of psoriasis treatment is to alleviate symptoms such as itching, redness, scaling, and discomfort. Various treatment modalities, including topical creams, phototherapy, oral medications, and biologic drugs, target different aspects of the disease to reduce inflammation, slow down skin cell growth, and promote healing of affected skin.
• Systemic drugs such as methotrexate, cyclosporine, and retinoids may be prescribed for moderate to severe psoriasis that doesn’t respond to other treatments.
• Biologic drugs are targeted therapies that block specific immune system pathways involved in psoriasis, such as TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors. They are often reserved for severe cases or when other treatments fail.
• Personalized medicineAdvances in genetic testing and understanding of immune system pathways may lead to personalized treatment plans tailored to an individual’s genetic makeup and disease characteristics.
• Novel biologic therapiesOngoing research aims to develop new biologic drugs with improved efficacy, safety profiles, and modes of administration.

Global Psoriasis Treatment Market Dynamics

The key market dynamics that are shaping the global psoriasis treatment market include

Key Market Drivers

• Increasing PrevalencePsoriasis is a common chronic skin condition affecting millions worldwide. As its prevalence continues to rise due to factors like genetic predisposition, environmental triggers, and lifestyle changes, the demand for effective treatments also grows.
• Advancements in Treatment OptionsThe development of new treatment modalities, including biologic drugs, targeted therapies, and advanced topical treatments, has revolutionized psoriasis management. These innovative therapies offer improved efficacy, safety profiles, and convenience compared to traditional options, driving market growth.
• Growing Awareness and EducationIncreased awareness about psoriasis among patients, healthcare providers, and the general public has led to earlier diagnosis and better management. Educational initiatives and advocacy efforts help reduce stigma, promote treatment-seeking behavior, and expand the patient pool for psoriasis treatments.
• Expanding Healthcare InfrastructureImproved access to healthcare services, particularly in emerging markets, has led to greater diagnosis and treatment of psoriasis. Investments in healthcare infrastructure, expanded insurance coverage, and government initiatives to address chronic diseases contribute to market growth.
• Shift towards Personalized MedicineAdvances in genetics and biomarker research have paved the way for personalized treatment approaches in psoriasis. Tailoring therapies to individual patient characteristics, such as genetic makeup, disease severity, and comorbidities, enhances treatment outcomes and drives demand for personalized treatment options.

 Key Challenges

• Efficacy VariabilityNot all treatments work equally well for every individual with psoriasis. Response to treatment can vary widely among patients, leading to challenges in achieving optimal outcomes and necessitating trial and error in finding the most effective therapy for each individual.
• Safety ConcernsSome psoriasis treatments, particularly systemic medications and biologics, carry potential risks of adverse effects, including infections, immunosuppression, and organ toxicity. Balancing the benefits of treatment with potential risks requires careful consideration and monitoring, especially in patients with comorbidities or compromised immune systems.
• High Cost of BiologicsBiologic drugs, while highly effective, are often expensive and may pose financial barriers to access for some patients. High treatment costs, coupled with limited insurance coverage or reimbursement, can restrict patient access to these advanced therapies, particularly in regions with resource constraints.
• Treatment AdherencePsoriasis treatment often requires long-term adherence to medications, lifestyle modifications, and regular follow-up appointments. Poor treatment adherence, due to factors such as medication complexity, side effects, or lack of patient education, can compromise treatment effectiveness and lead to disease flares or complications.
• Drug ResistanceProlonged use of certain psoriasis treatments, such as topical corticosteroids or systemic medications, may lead to drug resistance over time. Drug-resistant psoriasis poses challenges in disease management, requiring alternative treatment approaches or combination therapies to maintain disease control.

Key Trends

• Biologic Therapies DominanceBiologic drugs have revolutionized the treatment of moderate to severe psoriasis by targeting specific molecules involved in the inflammatory response. This trend is expected to continue, with biologics remaining a cornerstone of therapy due to their high efficacy and targeted mechanism of action.
• Personalized Medicine ApproachAdvances in genetics and biomarker research are paving the way for personalized treatment approaches in psoriasis. Tailoring treatment plans to individual patient characteristics, such as genetic makeup, disease severity, and comorbidities, allows for optimized treatment outcomes and enhanced patient satisfaction.
• Topical InnovationOngoing research and development efforts are focused on improving topical treatments for psoriasis, including novel formulations, combination therapies, and drug delivery technologies. Innovations such as foam formulations, nanoparticles, and microneedle patches aim to enhance drug penetration, efficacy, and patient compliance.
• Telemedicine and Digital Health SolutionsThe adoption of telemedicine and digital health platforms has accelerated in response to the COVID-19 pandemic and the need for remote healthcare delivery. Teleconsultations, virtual monitoring, and mobile health apps offer convenient access to dermatological care, facilitate treatment adherence, and improve patient engagement in psoriasis management.

Global Psoriasis Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global psoriasis treatment market

North America

• North America dominates the global psoriasis treatment market, driven by high disease prevalence, advanced healthcare infrastructure, and robust research and development activities.
• The United States accounts for the largest share of the market, with a significant presence of pharmaceutical companies, biotechnology firms, and academic institutions engaged in psoriasis research and drug development.
• Rising healthcare expenditure, favorable reimbursement policies, and increasing awareness about psoriasis contribute to market growth in the region.

Europe

• Europe is a key market for psoriasis treatment, characterized by a high burden of disease and well-established healthcare systems.
• Countries such as Germany, the United Kingdom, France, and Italy are major contributors to market revenue, with a strong focus on biologic therapies and personalized medicine approaches.
• Regulatory initiatives, such as the European Medicines Agency’s approval process for biologics and biosimilars, shape market dynamics and facilitate market access for innovative treatments.

Asia Pacific

• The Asia Pacific region represents a rapidly growing market for psoriasis treatment, driven by increasing disease awareness, improving healthcare infrastructure, and expanding access to innovative therapies.
• Countries such as China, Japan, India, and South Korea are key markets within the region, with a large patient population and rising healthcare expenditure.
• Market growth in Asia Pacific is fueled by the introduction of biosimilars, partnerships between multinational pharmaceutical companies and local manufacturers, and government initiatives to address chronic diseases.

Global Psoriasis Treatment MarketSegmentation Analysis

The Global Psoriasis Treatment Market is segmented based on Drug Class, Type, Route of Administration, Distribution Channel, and Geography.

Psoriasis Treatment Market, By Drug Class

• TNF Inhibitors
• Interleukins Inhibitors

So, when it comes to treating psoriasis, you've basically got two main types of drugsTNF Inhibitors and Interleukins Inhibitors. Historically, TNF inhibitors were the go-to choice, especially for those with moderate to severe psoriasis. But things are changing! Now, interleukin inhibitors – think specifically IL-17 and IL-23 inhibitors – are becoming a big deal. Why? Well, they seem to work even better, and they might be safer too. Plus, they're really good at targeting the specific things that cause psoriasis. For instance, IL-17 inhibitors, like secukinumab and ixekizumab, have shown some pretty amazing results in studies, which is why they're now often used as a first choice. And with new IL-23 inhibitors like guselkumab and risankizumab on the scene, there are even more options for patients. Basically, as we learn more, it looks like interleukin inhibitors are going to give those old TNF inhibitors a real run for their money in the psoriasis treatment world.

Psoriasis Treatment Market, By Type

• Plaque Psoriasis
• Psoriatic Arthritis

When it comes to treating psoriasis, we can break down the market by TypePlaque Psoriasis and Psoriatic Arthritis. Plaque psoriasis is really the big player here – it's the most common kind, with those raised, red, scaly patches, and it's what drives a lot of the demand for different treatments. You've got your creams, light therapy (phototherapy), pills, and those newer biologic drugs. Now, even though Psoriatic Arthritis affects a smaller group (up to 30% of psoriasis patients), it's growing fast! More people know about it now, we're getting better at spotting it early, and treatments are improving for both the skin and joint issues. Those biologic drugs – the ones that target inflammation, like TNF inhibitors and interleukin inhibitors – are doing a great job with psoriatic arthritis, which is definitely helping this part of the market grow.

Psoriasis Treatment Market, By Route of Administration

• Oral
• Parenteral/Systemic
• Topical

So, when it comes to how you actually take your psoriasis medication – the Route of Administration, as they say – the market's broken down into a few main pathsTopical (think creams and ointments), Parenteral/Systemic (like shots or infusions), and just swallowing pills – Oral. Right now, Topical treatments are king in the psoriasis world, mainly because they're easy to use, readily available, and work pretty well for mild to moderate cases. We're talking about stuff like corticosteroids, vitamin D buddies, retinoids, and those calcineurin inhibitor things. You just rub them right on your skin to calm down the inflammation and keep those symptoms in check. However, even though topical treatments are usually the first thing doctors try, the Parenteral/Systemic segment is really taking off. That's because more and more people are using those fancy biologic drugs and targeted therapies for more serious cases of psoriasis. These are given as injections or infusions, and they're super focused on taming inflammation. Plus, they're a great option if those topical creams or oral meds just aren't cutting it.

Psoriasis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

When it comes to how you get your psoriasis meds, it's mainly through Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies. Right now, retail pharmacies are the big guys. They're just easy to get to and have all sorts of stuff, both over-the-counter and prescription, to help manage psoriasis. Plus, you can usually chat with a pharmacist there about how to use the meds and what to watch out for. But, hey, online pharmacies are catching up fast! More and more people are buying stuff online these days, and that includes medicine. They've got a ton of choices for psoriasis treatments, often at good prices, and they deliver right to your door. So, a lot of folks are liking the ease and privacy of getting their healthcare stuff that way.

Psoriasis Treatment Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

So, when we look at where psoriasis treatments are popular, it breaks down geographically into North America, Europe, Asia Pacific, and the Rest of the World. Right now, North America is the biggest player, mainly because there are a lot of people with psoriasis there, they have really good healthcare, and there's a ton of research going on. You'll find all the big pharmaceutical companies and research institutions pushing things forward. But, hold on – Asia Pacific is catching up fast! They're becoming the second-largest market because people are learning more about the disease, getting better access to healthcare, and simply having more money to spend. Countries like China, Japan, and India are really investing in their healthcare systems and bringing in new treatments, which is why the market is booming there.

Key Players

The “Global Psoriasis Treatment Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novartis International AG, UCB, AstraZeneca, Celgene Corporation, Johnson & Johnson, Pfizer, Inc., Merck and Co. Inc,, AbbVie, Amgen, and Eli Lilly and Company. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Psoriasis Treatment Market Recent Developments

• In September 2022, Bristol Myers Squibb has received FDA approval for Sotyktu, an oral, allosteric tyrosine kinase 2-inhibitor, for treating moderate-to-severe plaque psoriasis in adults.
• In July 2022, Health Canada has approved the New Drug Submission review for Roflumilast cream, developed by Arcutis Biotherapeutics, Inc., for treating plaque psoriasis in adults and adolescents.
• In January 2022, UCB S.A. has been granted market authorization by the Japanese Ministry of Health, Labor, and Welfare for its drug Bimzelx, which is used to treat plaque psoriasis.

Report Scope

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorp